Switch theme
Sign up to access all valuation multiples
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
2000
355
LTM Revenue $90.3M
LTM EBITDA $4.1M
$58.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Harvard Bioscience has a last 12-month revenue (LTM) of $90.3M and a last 12-month EBITDA of $4.1M.
In the most recent fiscal year, Harvard Bioscience achieved revenue of $94.1M and an EBITDA of -$1.3M.
Harvard Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Harvard Bioscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $90.3M | XXX | $94.1M | XXX | XXX | XXX |
| Gross Profit | $52.3M | XXX | $54.8M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $4.1M | XXX | -$1.3M | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | -1% | XXX | XXX | XXX |
| EBIT | -$12.0M | XXX | -$6.2M | XXX | XXX | XXX |
| EBIT Margin | -13% | XXX | -7% | XXX | XXX | XXX |
| Net Profit | -$32.4M | XXX | -$12.4M | XXX | XXX | XXX |
| Net Margin | -36% | XXX | -13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $32.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Harvard Bioscience's stock price is $0.
Harvard Bioscience has current market cap of $19.8M, and EV of $58.9M.
See Harvard Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $58.9M | $19.8M | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Harvard Bioscience has market cap of $19.8M and EV of $58.9M.
Harvard Bioscience's trades at 0.6x EV/Revenue multiple, and -45.3x EV/EBITDA.
Equity research analysts estimate Harvard Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Harvard Bioscience has a P/E ratio of -0.6x.
See valuation multiples for Harvard Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.8M | XXX | $19.8M | XXX | XXX | XXX |
| EV (current) | $58.9M | XXX | $58.9M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 14.5x | XXX | -45.3x | XXX | XXX | XXX |
| EV/EBIT | -4.9x | XXX | -9.5x | XXX | XXX | XXX |
| EV/Gross Profit | 1.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -1.6x | XXX | XXX | XXX |
| EV/FCF | -2.3x | XXX | -32.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHarvard Bioscience's last 12 month revenue growth is 1%
Harvard Bioscience's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Harvard Bioscience's rule of 40 is 8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Harvard Bioscience's rule of X is 6% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Harvard Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Growth | 133% | XXX | -9% | XXX | XXX | XXX |
| Rule of 40 | 8% | XXX | -1% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 6% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 65% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Harvard Bioscience acquired XXX companies to date.
Last acquisition by Harvard Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Harvard Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Harvard Bioscience founded? | Harvard Bioscience was founded in 2000. |
| Where is Harvard Bioscience headquartered? | Harvard Bioscience is headquartered in United States of America. |
| How many employees does Harvard Bioscience have? | As of today, Harvard Bioscience has 355 employees. |
| Who is the CEO of Harvard Bioscience? | Harvard Bioscience's CEO is Mr. James W. Green. |
| Is Harvard Bioscience publicy listed? | Yes, Harvard Bioscience is a public company listed on NAS. |
| What is the stock symbol of Harvard Bioscience? | Harvard Bioscience trades under HBIO ticker. |
| When did Harvard Bioscience go public? | Harvard Bioscience went public in 2000. |
| Who are competitors of Harvard Bioscience? | Similar companies to Harvard Bioscience include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Harvard Bioscience? | Harvard Bioscience's current market cap is $19.8M |
| What is the current revenue of Harvard Bioscience? | Harvard Bioscience's last 12 months revenue is $90.3M. |
| What is the current revenue growth of Harvard Bioscience? | Harvard Bioscience revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Harvard Bioscience? | Current revenue multiple of Harvard Bioscience is 0.7x. |
| Is Harvard Bioscience profitable? | Yes, Harvard Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Harvard Bioscience? | Harvard Bioscience's last 12 months EBITDA is $4.1M. |
| What is Harvard Bioscience's EBITDA margin? | Harvard Bioscience's last 12 months EBITDA margin is 4%. |
| What is the current EV/EBITDA multiple of Harvard Bioscience? | Current EBITDA multiple of Harvard Bioscience is 14.5x. |
| What is the current FCF of Harvard Bioscience? | Harvard Bioscience's last 12 months FCF is -$25.4M. |
| What is Harvard Bioscience's FCF margin? | Harvard Bioscience's last 12 months FCF margin is -28%. |
| What is the current EV/FCF multiple of Harvard Bioscience? | Current FCF multiple of Harvard Bioscience is -2.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
